NovoCure (NVCR) Return on Sales (2014 - 2026)

NovoCure (NVCR) has reported Return on Sales for 13 consecutive years, with 0.0% the latest figure, recorded in Q2 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales climbed to 0.0% in Q2 2026 per NVCR's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for NVCR reached as high as 0.0% in Q1 2022 and fell as low as 0.0% in Q2 2023.
• A 5-year average of 0.0% and a median of 0.0% in 2025 frame the typical range for Return on Sales.
• The largest YoY upside for Return on Sales was 0 bps in 2022 against a maximum downside of 0 bps in 2022.
• Year by year, Return on Sales stood at 0.0% in 2022, then declined by 21 bps to 0.0% in 2023, then retreated by 16 bps to 0.0% in 2024, then jumped by 66 bps to 0.0% in 2025, then surged by 39 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.0% for Q2 2026, Q1 2026, and Q4 2025 respectively.